Bonus Content - Accredited Activities

As we recognize Kidney Cancer Awareness Month this March, advancements in renal cell carcinoma (RCC) treatment continue to evolve. Recently, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, a Nurse Practitioner and expert in genitourinary oncology, chaired the i3 Health’s NCPD activity titled Toxicity Management and Symptom Control in Advanced RCC: Playbook Update. In this interview, she shares updates in RCC treatment, strategies for toxicity management, and the importance of patient education.

Click here for the full NCPD activity! https://i3health.com/course-information/toxicity-management-and-symptom-control-in-advanced-rcc-playbook-update

Additional Advances in Renal Cell Carcinoma Research and Clinical Trials With Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month.   



Click the link for the full activity! https://bit.ly/4hyVwLn

Additional Advances in Stem Cell Mobilization Research and Clinical Trials in Multiple Myeloma With Hamza Hashmi, MD

The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical.

In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease.

Don’t miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice.

Click below to access these valuable resources:

Accredited CME/NCPD Podcast: bit.ly/3B4gSB1
Position Statement in Blood Cancer Journal: www.nature.com/articles/s41408-024-01129-0
Live Task Force Recording: www.youtube.com/live/TILCPB6w3Ig?…=1Z8m4dA2qwLJd6rN

Additional Advances in Relapsed/Refractory Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP


Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs.

In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration.

Don’t miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!

Register Here! 

July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registration

August 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration

Exploring the Evolution of Neuroendocrine Tumor Diagnostics and Therapeutics: A Webinar Preview With Aman Chauhan, MD

oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM.

In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration.

Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!

Register Here: bit.ly/3UgV7nF

Unmasking Hereditary ATTR-CM: A Webinar Preview With Mathew Maurer, MD

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 2 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies"

Don't forget to claim your credit after the episode!

Click on the link to claim your credit for module 2: bit.ly/43VoFNP

Additional Advances in Systemic Mastocytosis With Mariana Castells, MD, PhD + Module 2

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai 

In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

Improving Early and Equitable Lung Cancer Detection With Sybil: Mary Pasquinelli, DNP, FNP-BC, CTTS, and Waqas Haque

Time is running out to access this essential CME/NCPD-approved podcast! Join renowned dermatology experts Dr. Peter A. Lio and Dr. Linda F. Stein Gold as they dive into the latest evidence and best practices for treating atopic dermatitis in children and adolescents. With new therapies rapidly changing the treatment landscape, this podcast delivers the practical insights you need to confidently diagnose, evaluate, and manage pediatric atopic dermatitis.

Don’t miss your chance to:

-Get up to speed on novel and emerging therapies, including nonsteroidal topicals, JAK inhibitors, and monoclonal antibodies
-Learn how to recognize key clinical features that inform the differential diagnosis
-Discover strategies to optimize outcomes and quality of life for your young patients

This activity is expiring soon—listen now to stay current and earn credit before it’s gone!

Click here to claim your CME/NCPD credit: bit.ly/4nGZhBG

EXPIRING SOON! Best Practices & Breakthroughs in Pediatric Atopic Dermatitis

LAST CHANCE – Expires November 21!

Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.


Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T

EXPIRING SOON! Diagnosis and Management of Dedifferentiated Liposarcoma

LAST CHANCE – Expires November 21!

Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.

Listen now and earn 0.5 CME credit: bit.ly/49GyP5T

Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.

In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!

Click here to claim CME/NCPD credit: bit.ly/49NCaQu

EXPIRING SOON! What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: Actionable Insights and Testing Recommendations

Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.

In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!

Click here to claim CME/NCPD credit: bit.ly/405xEJO

EXPIRING SOON! What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.

The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!

Tuesday, January 13 at 5:00 pm ET - https://bit.ly/4p7HRil
Monday, February 2 at 7:00 pm ET - https://bit.ly/495gnEd


Discovering Systemic Mastocytosis in Practice: A Webinar Preview With Lauren M. Madigan, MD

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Additional Advances in Systemic Mastocytosis With Mariana Castells, MD, PhD + Module 2

Oncology Data Advisor®

Related tracks